ArticlePloS one2025

First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.

Jing-Wen Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.